

Figure S1: Specificity of the siRNAs used in the study. A. Western blots showing the DAP5 and eIF4GI protein levels upon si DAP5 treatment. **B.** Western blots showing the DAP5 and eIF4GI protein levels upon silencing using si eIF4GI. β-Actin protein levels are indicated as loading control.



Figure S2: MTT assay performed on cells transfected with either siDAP5, si4GI or siNsp. At 30 hours post transfection, cells were treated with 0.5 mg/ml of MTT reagent and absorbance was measured at 550 nm after 3 hours.



Figure S3: Effect of 2A protease on CVB3 IRES activity using bicistronic construct. *In vitro* transcribed capped CVB3 bicistronic RNA was transfected in cells previously transfected with plasmid expressing 2A protease or vector control. 8 hours post transfection of bicistronic RNA, cells were processed for luciferase assay. F luc activity represents CVB3 IRES mediated translation and R luc activity represents cap-dependent translation.



Figure S4: Structural alignment of MIF4G domains of DAP5 (grey) and eIF4GI (magenta). The CVB3 IRES interacting regions (adapted from de Breyne et al., 2009, (5)) in DAP5 and eIF4GI are indicated by yellow and green color respectively. The amino acid composition in the interacting region is indicated in the box.



Figure S5.A. Purified recombinant DAP5 protein from bacteria. The * mark indicates the bacterial contaminants that co-purified along with DAP5 protein. **B.** UV crosslinking experiment carried out with recombinant protein obtained in panel A. As can be observed in the gel, the contaminant proteins were not found to be interacting with CVB3 5'UTR. **C.** Purified recombinant C-terminal eIF4GI protein.

KF537633.1	CCCAACCACGGAGCAAGTAGTTGCAAACCAGCAACCAGCTTGTCGTAACGCGTAAGTCTG	532
DQ890386.1	CCCAACCACGGAGCAAGTGCTCACAAACCAGTGAGTGGCTTGTCGTAACGGGTAACTCTG	530
KJ849619.1	CCTAACTGCGGAGCAGATACCCACGCACCAGTGGGCAGTCTGTCGTAACGGGCAACTCTG	512
MG780414.1	CCTAACTGCGGAGCAGATACCCACACGCCAGTGGGCAGTCTGTCGTAATGGGCAACTCTG	524
AJ493062.2	CCCAACTGCGGAGCAGGTACCCACACACAGTGGGCAGCCTGTCGTAACGGGCAACTCTG	532
JQ729993.1	CCTAACTGCGGAGCAGATACCCACATGCCAGTGGGCAGTCTGTCGTAACGGGCAACTCTG	533
AB705308.1	CCTAACTGCGGAGCAGATACCTACATGCCAGTGGGCGGTCTGTCGTAACGGGCAACTCTG	532
KC570453.1	CCCAACTGCGGAGCACACGCCCACAAGCCAGCGGGTAGTGTCGTAACGGGTAACTCTG	530
M33854.1	CCTAACTGCGGAGCACACACCCTCAAGCCAGAGGGCAGTGTCGTAACGGGCAACTCTG	531
M88483.1	CCTAACTGCGGAGCACACACCCTCAAGCCAGAGGGCAGTGTGTCGTAACGGGCAACTCTG	532
	** *** ******* * **** * ******** * ** *	
WEE 37 (33 1	#222223 2222 0F3 0F7#220F0#220F0#220-#F7#23 #####3 23 28220#22##3	5.0.1
NF337633.1		291
DQ890386.1	Caccocal account of the contract of the contract of the traction of the contract of the contra	571
MC700414 1		202
AT402062 2		503
10720002.2		231
ND705200 1		501
xc570452 1		291
M2206/ 1		500
M00402 1		590
M00403.1		291
KF537633.1	TGGTGACAATC-ATAGATTGTTATCATAAGGCGAATTGGATTGG	650
DQ890386.1	TGGTGACAATC-AGAGATTGTTATCATAAAGCGTATTGGATTGG	648
KJ849619.1	TGGTGACAATTGAAAGATTGTTACCATATAGC-TATTGGATTGG	630
MG780414.1	TGGTGACAATTGAGAGATTGTTACCATATAGC-TATTGGATTGG	642
AJ493062.2	TGGTGACAATTGAAAGATTGTTACCATATAGC-TATTGGATTGG	650
JQ729993.1	TGGTGACAATTGAGAGATTGTTACCATATAGC-TATTGGACTGGCCATCTGGTGACAAAC	651
AB705308.1	TGGTGACAATTGAGAGATTGTTACCATATAGC-TATTGGATTGG	650
KC570453.1	TGGTGACAATTAAAGAATTGTTACCATATAGC-TATTGGATTGG	648
M33854.1	TGGTGACAATTGAGAGATCGTTACCATATAGC-TATTGGATTGG	649
M88483.1	TGGTGACAATTGAGAGATTGTTACCATATAGC-TATTGGATTGG	650
	******** * ** **** **** ** ***** *****	

Figure S6: Multiple sequence alignment of 5' UTR from different picornaviruses. The box indicates conserved eIF4GI and DAP5 binding sites. KF537633.1- Human poliovirus 1, DQ890386.1- Human poliovirus 2, KJ849619.1-Human coxsackievirus B1, MG780414.1- Coxsackievirus B1, AJ493062.2- Human enterovirus 77, JQ729993.1- Human echovirus 6, AB705308.1- Echovirus E6, KC570453.1- Human enterovirus 71, M33854.1- Coxsackievirus B3